Active substanceMeldoneyMeldoney
Similar drugsTo uncover
  • Angiocarcinoma
    solution for injections 
  • Vazomag
    solution for injections 
    Olainfarm, AO     Latvia
  • Idrinol®
    solution in / in d / eye 
  • Idrinol®
    capsules inwards 
    Olainfarm, AO     Latvia
  • Cardionate®
    solution for injections 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    MAKIZ-PHARMA, LLC     Russia
  • Meldoney
    solution in / in d / eye w / m 
    ELLARA, LTD.     Russia
  • Meldoney
    capsules inwards 
  • Meldoney
    solution for injections 
    BIOCHEMIST, OJSC     Russia
  • Meldoney
    solution for injections 
  • Meldoney
    solution for injections 
    ATOLL, LLC     Russia
  • Meldoney
    solution for injections 
    BIOSINTEZ, PAO     Russia
  • Meldonius Organica
    solution for injections 
    ORGANICS, JSC     Russia
  • Meldonium-Binergia
    solution in / in d / eye 
    BINERGIYA, CJSC     Russia
  • Meldonij DECO
    solution for injections 
    Company DEKO, LLC     Russia
  • Meldonius-SOLOFARM
    solution for injections 
    GROTEKS, LLC     Russia
  • Meldonius-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Melfor®
    solution for injections 
    AVISTA, LLC     Russia
  • Melfor®
    capsules inwards 
       
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    solution w / m in / in d / eye 
    GRINDEX, JSC     Latvia
  • Dosage form: & nbspinjection
    Composition:

    Composition per ml of solution:

    Meldonium dihydrate (trimethylhydrasine propionate dihydrate) based on the dihydrate without moisture adsorption - 100 mg

    in terms of anhydrous substance - 80.2 mg,

    Water for injection - up to 1 ml.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    C.01.E.B.22   Meldoney

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Analog gamma-butyrobetaine, inhibits gamma butirobetaingidroksinazu, reduces the synthesis of carnitine and transportation of long chain fatty acids across cell membranes and prevents the accumulation of cells in the activated forms of unoxidized fatty acids - acylcarnitine derivatives and atsilkoenzima A. ischemia restores the balance of oxygen delivery processes and its use in cells, prevents disruption of ATP transport; simultaneously activates glycolysis (which proceeds without additional oxygen consumption. By lowering the carnitine concentration intensively synthesized gamma-butyrobetaine possesses vasodilating properties.The mechanism of action determines the variety of its pharmacological effects: increasing efficiency, reducing the symptoms of mental and physical overstrain, the activation of tissue and humoral immunity, cardioprotective action. In the case of acute ischemic damage, the myocardium slows the formation of the necrotic zone, shortens the rehabilitation period. With heart failure increases myocardial contractility, increases exercise tolerance, reduces the incidence of angina attacks. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of the ischemic site. Effective in the case of vascular and dystrophic pathology of the fundus. Characteristic is also a tonic effect on the central nervous system, the elimination of functional disorders of the somatic and autonomic nervous systems in alcoholics during the period of abstinence.

    Indications:

    As a part of combined therapy of coronary heart disease, chronic heart failure, cardialgia against dyshormonal myocardial dystrophy.

    Acute and chronic forms of cerebral circulation disorders.

    Acute circulatory disorders in the retina, hemophthalmia and hemorrhage into the retina of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (including diabetic and hypertensive) - only for parabulbar injection.

    Complex therapy of abstinence alcohol syndrome.

    Reduced performance, physical overexertion (including athletes), postoperative period to accelerate rehabilitation.

    Contraindications:Hypersensitivity, increased intracranial pressure (with violation of venous outflow and intracranial tumors), pregnancy, lactation.
    Pregnancy and lactation:Not recommended in pregnancy (safety of use is not proven). At the time of treatment, breastfeeding should be discontinued (it is not known whether it penetrates breast milk).
    Dosing and Administration:

    As a part of combined therapy of coronary heart disease, chronic heart failure, cardialgia against dyshormonal myocardial dystrophy intravenously, 0.5-1.0 g once a day, or intramuscularly 0.5 g 1-2 times a day, course treatment - 10-14 days, then go to oral intake.

    Violation of cerebral circulation: the acute phase of cerebrovascular pathology - intravenously, 0.5 g once a day for 10 days, then switch to oral administration.

    Chronic disorders of cerebral circulation: intramuscular by 0,5 g once a day, the course of treatment is 10-14 days, then switch to oral administration.

    Acute disorders of blood circulation in the retina, hemophthalmia and hemorrhage into the retina of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (including diabetic and hypertensive) - retrobulbarno and subconjunctival 0.5 ml of 10% solution for 10 days.

    An abstinent alcoholic syndrome - intravenously or intramuscularly at 0.5 g 2 times a day. The course of treatment is 7-10 days.

    Reduced performance, physical overexertion (including athletes), postoperative period to accelerate rehabilitation - intravenously, 0.5-1.0 g once a day, or intramuscularly 0.5 g 1-2 times a day . The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.

    Side effects:Rarely - skin itching, dyspepsia, tachycardia, agitation, lowering blood pressure.
    Interaction:Strengthens the coronarodilating and some hypotensive drugs, cardiac glycosides. You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmic drugs, diuretics, bronchodilators. In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, hypotensive drugs and peripheral vasodilators.
    Form release / dosage:Solution for injection 100 mg / ml.
    Packaging:

    5 ml in ampoules. By 5 or 10 ampoules in a contiguous cell package of a polyvinylchloride film and aluminum foil or 5 ampoules in a contiguous cell pack of a polyethylene terephthalate film. 1 or 2 contour squares in a cardboard bundle.

    The package inserts instructions for medical use.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-006481/08
    Date of registration:13.08.2008
    The owner of the registration certificate:FARMSTANDART-UFAVITA, JSC FARMSTANDART-UFAVITA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.03.2016
    Illustrated instructions
      Instructions
      Up